Vermillion Sets Fourth Quarter and Full Year 2013 Conference Call for Thursday, March 6, 2014

    Vermillion Sets Fourth Quarter and Full Year 2013 Conference Call for
                           Thursday, March 6, 2014

PR Newswire

AUSTIN, Texas, Feb. 26, 2014

AUSTIN, Texas, Feb. 26, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML),
a multivariate diagnostics company focused on gynecologic cancers and women's
health, will hold a conference call on Thursday, March 6, 2014, at 4:30 p.m.
Eastern time to discuss results for the fourth quarter and year ended December
31, 2013. Financial results will be issued in a press release prior to the
call.

Vermillion's President and CEO Thomas McLain will host the call, followed by a
question and answer period.

Date: Thursday, March 6, 2014
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-in number: 1-800-763-6049
International dial-in number: 1-212-231-2932
Conference ID: 21709303
Webcast: http://edge.media-server.com/m/p/ee5rni5o/lan/en

The conference call will be webcast live and available for replay via the
investor section of the company's website at www.vermillion.com.

Please call the conference telephone number five minutes prior to the start
time. An operator will register your name and organization. If you have any
difficulty connecting with the conference call, please contact Liolios Group
at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call
until March 20, 2014.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay ID: 21709303

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in gynecologic
oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical
assessment of ovarian tumors for malignancy, using an innovative algorithmic
approach. As the first FDA-cleared, protein-based In Vitro Diagnostic
Multivariate Index Assay, OVA1 represents a new class of software-based
diagnostics. For additional information, including published clinical trials,
visit www.vermillion.com.

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 1-949-574-3860
vrml@liolios.com

SOURCE Vermillion, Inc.

Website: http://www.vermillion.com
 
Press spacebar to pause and continue. Press esc to stop.